CA2237335A1 - The use of cholinesterase inhibitors in the treatment of xerostomia - Google Patents

The use of cholinesterase inhibitors in the treatment of xerostomia

Info

Publication number
CA2237335A1
CA2237335A1 CA002237335A CA2237335A CA2237335A1 CA 2237335 A1 CA2237335 A1 CA 2237335A1 CA 002237335 A CA002237335 A CA 002237335A CA 2237335 A CA2237335 A CA 2237335A CA 2237335 A1 CA2237335 A1 CA 2237335A1
Authority
CA
Canada
Prior art keywords
xerostomia
treatment
cholinesterase inhibitors
cholinesterase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002237335A
Other languages
French (fr)
Other versions
CA2237335C (en
Inventor
Jorgen Ekstrom
Herbert Helander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CALABAR AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9504267A external-priority patent/SE9504267D0/en
Application filed by Individual filed Critical Individual
Publication of CA2237335A1 publication Critical patent/CA2237335A1/en
Application granted granted Critical
Publication of CA2237335C publication Critical patent/CA2237335C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine

Abstract

There is provided the use of a cholinesterase inhibitor in the manufacture of a medicament for topical administration for use in the treatment of xerostomia.
CA002237335A 1995-11-29 1996-11-25 The use of cholinesterase inhibitors in the treatment of xerostomia Expired - Fee Related CA2237335C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9504267A SE9504267D0 (en) 1995-11-29 1995-11-29 New therapeutic use
SE9504267-7 1995-11-29
PCT/SE1996/001531 WO1997019685A1 (en) 1995-11-29 1996-11-25 The use of cholinesterase inhibitors in the treatment of xerostomia

Publications (2)

Publication Number Publication Date
CA2237335A1 true CA2237335A1 (en) 1997-06-05
CA2237335C CA2237335C (en) 2007-06-05

Family

ID=38137603

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002237335A Expired - Fee Related CA2237335C (en) 1995-11-29 1996-11-25 The use of cholinesterase inhibitors in the treatment of xerostomia

Country Status (1)

Country Link
CA (1) CA2237335C (en)

Also Published As

Publication number Publication date
CA2237335C (en) 2007-06-05

Similar Documents

Publication Publication Date Title
CA2239174A1 (en) Novel compounds with analgesic effect
CA2186039A1 (en) New oral pharmaceutical dosage form
CA2274074A1 (en) Novel compounds with analgesic effect
CA2173976A1 (en) Phenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders
CA2218714A1 (en) Dosage form comprising oxybutynin
EP1743630A3 (en) Pharmaceutical combination
HUP9900028A3 (en) Pharmaceutically active quinazoline compounds, their production, use thereof and medicament containing them
CA2125662A1 (en) Transdermally administered system containing acetylsalicylic acid for thrombosis therapy and cancer prophylaxis
CA2179015A1 (en) Use of bis(amidinobenzimidazoles) in the manufacture of medicament for inhibiting retroviral integrase
CA2158609A1 (en) 5 .alpha.-reductase inhibitors
AU6698996A (en) A film for topical use in the treatment of wounds
AU6946491A (en) Orally active renin inhibitors
CA2190837A1 (en) Transdermal delivery of anti-epileptic drugs
AU1956092A (en) Pharmaceutical agent for treatment of withdrawal symptoms
EP0765661A3 (en) Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of glumerulonephritis
HUP9901990A2 (en) Furan- and thiophene derivatives having inhibitor effect on the replication of hiv-1 and hiv-1 mutants, and medicaments containing the same
CA2120319A1 (en) Pharmaceutical for the treatment of skin disorders
AU1870292A (en) Use of neutral endopeptidase inhibitors in the treatment of nephrotoxicity
CA2235951A1 (en) Novel uses of mammalian ctla-8 and related reagents
SE9504267D0 (en) New therapeutic use
CA2237335A1 (en) The use of cholinesterase inhibitors in the treatment of xerostomia
AU7726796A (en) Use of 3-oxa-d-prostaglandins for the manufacture of a medicament for the treatment of glaucoma
AU4179497A (en) Use of PKC inhibitors for the manufacture of a medicament for the treatment f AIDS
CA2179634A1 (en) 4-arylisoindole analgesics
AU6355296A (en) Use of a non-nucleoside reverse transcriptase inhibitor in a ssociation with nucleoside inhibitors for the treatment of h iv infection

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed